Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psorias ...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for moderate-to-severe plaque psoriasis in adults and pediatric ...
Pearson and Tata Consultancy Services have formed a multi-year partnership to help enterprises develop future-ready workforces by combining AI-powered learning, assessment, and cloud-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results